期刊
ANTIVIRAL THERAPY
卷 15, 期 -, 页码 17-24出版社
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1526
关键词
-
资金
- Bristol-Myers Squibb
- Abbott Laboratories
- Gilead
- MSD
- GlaxoSmithKline
- Pharmacia
- Pfizer
- Boehringer-Ingelheim
- Roche
- Schering-Plough
- Swedish Orphan
- Tibotec
HIV testing policies and practices vary widely across Europe. It is clear that there are individuals who might present late for HIV diagnosis and care within all risk groups, and potentially in any healthcare setting. This article explores the need to ensure earlier identification and treatment of late-presenting patients by reviewing strategies that might be considered. Such strategies could include routine provider-initiated HIV testing of at-risk groups in settings such as sexually transmitted infection clinics, drug dependency programmes or antenatal care. Healthcare providers might also consider routine HIV testing in all healthcare facilities, in settings including emergency and primary care, where local HIV prevalence is above a threshold that should be further evaluated. They should also take advantage of rapid testing technologies and be aware of barriers to HIV testing among specific groups to provide opportunities for testing that are relevant to local communities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据